Ampyra FDA Approval History
FDA Approved: Yes (First approved January 22, 2010)
Brand name: Ampyra
Generic name: dalfampridine
Dosage form: Extended Release Tablets
Previous Name: Fampridine-SR
Company: Acorda Therapeutics, Inc.
Treatment for: Multiple Sclerosis
Ampyra (dalfampridine) is an oral potassium channel blocker indicated to improve walking ability in people with multiple sclerosis.
Development timeline for Ampyra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.